Imricor Medical (Australia) Performance
| IMR Stock | 1.16 0.06 5.45% |
Imricor Medical holds a performance score of 17 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 1.63, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Imricor Medical will likely underperform. Use Imricor Medical Systems treynor ratio, value at risk, and the relationship between the sortino ratio and maximum drawdown , to analyze future returns on Imricor Medical Systems.
Risk-Adjusted Performance
17 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Imricor Medical Systems are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Imricor Medical unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Imricor prepares for 2025 US commercial launch - ShareCafe | 10/16/2024 |
| Begin Period Cash Flow | 5.7 M |
Imricor |
Imricor Medical Relative Risk vs. Return Landscape
If you would invest 55.00 in Imricor Medical Systems on September 3, 2024 and sell it today you would earn a total of 61.00 from holding Imricor Medical Systems or generate 110.91% return on investment over 90 days. Imricor Medical Systems is generating 1.3102% of daily returns assuming 5.7892% volatility of returns over the 90 days investment horizon. Simply put, 51% of all stocks have less volatile historical return distribution than Imricor Medical, and 74% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Imricor Medical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Imricor Medical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Imricor Medical Systems, and traders can use it to determine the average amount a Imricor Medical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2263
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | IMR | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.79 actual daily | 51 51% of assets are less volatile |
Expected Return
| 1.31 actual daily | 26 74% of assets have higher returns |
Risk-Adjusted Return
| 0.23 actual daily | 17 83% of assets perform better |
Based on monthly moving average Imricor Medical is performing at about 17% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Imricor Medical by adding it to a well-diversified portfolio.
Imricor Medical Fundamentals Growth
Imricor Stock prices reflect investors' perceptions of the future prospects and financial health of Imricor Medical, and Imricor Medical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Imricor Stock performance.
| Return On Equity | -2.75 | ||||
| Return On Asset | -1.25 | ||||
| Operating Margin | (19.77) % | ||||
| Current Valuation | 328.6 M | ||||
| Shares Outstanding | 270.18 M | ||||
| Price To Book | 3.97 X | ||||
| Price To Sales | 370.37 X | ||||
| Revenue | 615.57 K | ||||
| Gross Profit | (1.53 M) | ||||
| EBITDA | (21.87 M) | ||||
| Net Income | (34.09 M) | ||||
| Total Debt | 10.42 M | ||||
| Book Value Per Share | (0.03) X | ||||
| Cash Flow From Operations | (19.55 M) | ||||
| Earnings Per Share | (0.17) X | ||||
| Total Asset | 8.31 M | ||||
| Retained Earnings | (165 M) | ||||
About Imricor Medical Performance
Assessing Imricor Medical's fundamental ratios provides investors with valuable insights into Imricor Medical's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Imricor Medical is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Imricor Medical is entity of Australia. It is traded as Stock on AU exchange.Things to note about Imricor Medical Systems performance evaluation
Checking the ongoing alerts about Imricor Medical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Imricor Medical Systems help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Imricor Medical is way too risky over 90 days horizon | |
| Imricor Medical may become a speculative penny stock | |
| Imricor Medical appears to be risky and price may revert if volatility continues | |
| Imricor Medical has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 615.57 K. Net Loss for the year was (34.09 M) with loss before overhead, payroll, taxes, and interest of (1.53 M). | |
| Imricor Medical generates negative cash flow from operations | |
| About 20.0% of the company shares are held by company insiders |
- Analyzing Imricor Medical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Imricor Medical's stock is overvalued or undervalued compared to its peers.
- Examining Imricor Medical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Imricor Medical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Imricor Medical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Imricor Medical's stock. These opinions can provide insight into Imricor Medical's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Imricor Stock Analysis
When running Imricor Medical's price analysis, check to measure Imricor Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imricor Medical is operating at the current time. Most of Imricor Medical's value examination focuses on studying past and present price action to predict the probability of Imricor Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imricor Medical's price. Additionally, you may evaluate how the addition of Imricor Medical to your portfolios can decrease your overall portfolio volatility.